A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of recombinant
anti-PD-1 humanized monoclonal antibody injection (609A) in patients with unresectable or
advanced undifferentiated pleomorphic sarcoma